"...has a newsletter recommended them?" I don't know @gmac, but...

"...has a newsletter recommended them?"

I don't know @gmac, but I can understand why an astute newsletter editor might be focussing on CTE:

1. Uncertainty about Cell Care sell-down depressing the SP now removed;

2. New substantial shareholder announcement imminent;

3. Company share-buy back scheme to start in mid-April;

4. Cash backing of $4.3m;

5. Enterprise value at a humble ~$6m;

6. No debt;

7. First half revenue up 18.5% after a 30% rise in clinical trials revenue;

8. Pivotal and unique moated exposure to the national clinical trials industry and the exploding medicinal cannabis market.

And all of this for a stock that's ~50% below its 52 week high. Conclusion: I see scope for material improvement in the SP.